Chronic Weight Management

Chronic Weight Management

Chronic weight management treats obesity as a long-term, relapsing disease rather than something a short course of treatment can fix. It draws on several disciplines. The approach accepts that obesity involves lasting changes in energy balance, appetite control and the body’s metabolic set point, all of which resist weight loss and push weight back up. Effective care usually combines behavior change (diet, more physical activity and cognitive behavioral strategies) with medication and, for eligible patients, metabolic or bariatric surgery. The goal is to reach and keep a clinically meaningful weight loss, usually defined as at least 5% of starting body weight, which is linked to better cardiometabolic risk factors.

Incretin-based drugs have changed drug treatment for weight management. Older obesity drugs produced modest weight loss of 3-7% and were limited by tolerability and safety problems. GLP-1 receptor agonists such as semaglutide, and dual or triple agonists such as tirzepatide and retatrutide, have produced weight reductions of 15-25% or more in clinical trials, close to some bariatric operations. But the evidence consistently shows weight returns when treatment stops, so many patients need long-term or indefinite medication.

Clinical Relevance to Retatrutide

Retatrutide is a major step forward for chronic weight management because it activates three receptors: GLP-1, GIP and glucagon. In phase 2 clinical trials, it produced mean weight reductions above 24% at the highest doses over 48 weeks, among the largest seen with any drug. The gradual dose increases used in retatrutide trials help limit gastrointestinal side effects at the start, which makes the drug easier to tolerate and stay on. As with other obesity drugs, ongoing maintenance treatment with retatrutide is expected to be needed to keep weight off, and ongoing studies are testing its long-term efficacy and safety.